Page last updated: 2024-12-10

merbarone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

merbarone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4990817
CHEMBL ID1765797
SCHEMBL ID10817881
MeSH IDM0132159

Synonyms (26)

Synonym
97534-21-9
merbarone
merbarone, >=98% (hplc), solid
nsc 336628
5-pyrimidinecarboxamide, hexahydro-4,6-dioxo-n-phenyl-2-thioxo-
NCGC00165827-01
5-(n-phenylcarboxamido)-2-thiobarbituric acid
HSCI1_000067
CHEMBL1765797 ,
ywb9if596v ,
unii-ywb9if596v
ccris 8215
5-(n-phenylcarbamoyl)-2-thiobarbituric acid
FT-0630995
SCHEMBL10817881
DTXSID9031567
hexahydro-4,6-dioxo-n-phenyl-2-thioxo-5-pyrimidinecarboxamide
us9428466, merbarone
bdbm241949
4,6-dioxo-n-phenyl-2-thioxohexahydropyrimidine-5-carboxamide
merbarone - cas 97534-21-9
MS-23710
XDA53421
CS-0014735
HY-19024
AKOS040748903

Research Excerpts

Overview

Merbarone, NSC 336628, is an investigational anticancer drug with activity against experimental animal tumors including melanoma. Merbarone is a catalytic inhibitor of DNA topoisomerase (topo) II that does not stabilize DNA-topo II cleavable complexes.

ExcerptReferenceRelevance
"Merbarone is a derivative of thiobarbituric acid, possessing catalytic inhibitory potential against human topoisomerase IIα (hTopoIIα). "( Pharmacoinformatics analysis of merbarone binding site in human topoisomerase IIα.
Bharatam, PV; Guchhait, SK; Tripathi, N, 2019
)
2.24
"Merbarone is a catalytic inhibitor of topoisomerase II (topo II) that has been proposed to act primarily by blocking topo II-mediated DNA cleavage without stabilizing DNA-topo II-cleavable complexes. "( Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Eastmond, DA; Wang, L, 2002
)
1.97
"Merbarone, NSC 336628, is an investigational anticancer drug with activity against experimental animal tumors including melanoma. "( Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.
Flaherty, LE; Kraut, EH; Liu, PY; Natale, RB; Slavik, M; Sondak, VK, 1995
)
2.09
"Merbarone is a catalytic inhibitor of DNA topoisomerase (topo) II that does not stabilize DNA-topo II cleavable complexes. "( Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Beck, WT; Boege, F; Kusumoto, H; Raimondi, SC; Rodgers, QE, 1996
)
1.96
"Merbarone is a catalytic inhibitor of topoisomerase II that is in clinical trials as an anticancer agent. "( Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.
Fortune, JM; Osheroff, N, 1998
)
3.19

Effects

ExcerptReferenceRelevance
"Merbarone has previously been shown to have antitumor activity of unknown mechanism in P388 and L1210 tumor models (A. "( In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Bartus, JO; Drake, FH; Hertzberg, RP; Hofmann, GA; Johnson, RK; Mattern, MR; Mirabelli, CK; Mong, SM, 1989
)
1.95

Actions

ExcerptReferenceRelevance
"Merbarone failed to increase colony formation."( Effects of DNA topoisomerase II inhibitors on human bone marrow progenitor cells.
Berney, JJ; Chresta, CM; Delgado, C; Francis, GE; Patel, P; Tejedor, MC, 1994
)
1.01

Dosage Studied

ExcerptRelevanceReference
" Preclinical studies suggested that the antitumor effects of this drug were schedule dependent, since repeated dosing increased killing of tumor cells when compared to intermittent injections."( Phase I clinical and pharmacological study of merbarone.
Baltzer, L; Dimaggio, JJ; Haines, I; Lee, SJ; Lowenthal, DA; Muindi, J; Stevens, YW; Walsh, TD; Warrell, RP; Yaldaei, S, 1990
)
0.54
" Seventeen patients were treated at a starting dose of 1000 mg/m2/day for 5 days by continuous intravenous infusion; the dose was escalated in accordance with the toxicity experienced, and no dosage reductions owing to toxicity were required."( A phase II study of merbarone in patients with adenocarcinoma of the pancreas.
Ajani, JA; Daugherty, KR; Jones, DV; Krakoff, IH; Levin, B; Winn, RJ, 1993
)
0.61
" Etoposide was administered at a dosage of 30 or 60 mg/kg."( Dominant lethal mutations of topoisomerase II inhibitors etoposide and merbarone in male mice: a mechanistic study.
Attia, SM, 2012
)
0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)51.60000.48004.35649.9400AID1471728; AID1547964; AID1547965; AID591712; AID779597
Xanthine dehydrogenase/oxidaseHomo sapiens (human)IC50 (µMol)274.00000.00132.81389.8200AID1649927
Solute carrier family 22 member 12Homo sapiens (human)IC50 (µMol)5.40000.02602.61527.3000AID1649928
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
allantoin metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of protein phosphorylationXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell proliferationXanthine dehydrogenase/oxidaseHomo sapiens (human)
guanine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
inosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyinosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
adenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyadenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyguanosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
AMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
IMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
lactationXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of gene expressionXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron-sulfur cluster assemblyXanthine dehydrogenase/oxidaseHomo sapiens (human)
amide catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell differentiationXanthine dehydrogenase/oxidaseHomo sapiens (human)
GMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dGMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dAMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of p38MAPK cascadeXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vasculogenesisXanthine dehydrogenase/oxidaseHomo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 12Homo sapiens (human)
response to xenobiotic stimulusSolute carrier family 22 member 12Homo sapiens (human)
urate transportSolute carrier family 22 member 12Homo sapiens (human)
cellular homeostasisSolute carrier family 22 member 12Homo sapiens (human)
cellular response to insulin stimulusSolute carrier family 22 member 12Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 12Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 12Homo sapiens (human)
renal urate salt excretionSolute carrier family 22 member 12Homo sapiens (human)
organic anion transportSolute carrier family 22 member 12Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron ion bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein homodimerization activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
FAD bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
urate transmembrane transporter activitySolute carrier family 22 member 12Homo sapiens (human)
PDZ domain bindingSolute carrier family 22 member 12Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
peroxisomeXanthine dehydrogenase/oxidaseHomo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
sarcoplasmic reticulumXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
plasma membraneSolute carrier family 22 member 12Homo sapiens (human)
membraneSolute carrier family 22 member 12Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 12Homo sapiens (human)
brush border membraneSolute carrier family 22 member 12Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 12Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1434589Inhibition of human topoisomerase-2 alpha expressed in baculovirus infected insect cells assessed as reduction in enzyme-meditaed supercoiled pRYG DNA substrate relaxation at 100 uM in presence of buffer containing DTT after 30 mins by agarose gel electro2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis and biological evaluation of naphthoquinone-coumarin conjugates as topoisomerase II inhibitors.
AID779597Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 after 1 hr by ethidium bromide staining2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Further SAR studies on bicyclic basic merbarone analogues as potent antiproliferative agents.
AID1471733Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1547964Inhibition of human topo2alpha incubated for 30 mins by SYBR safe DNA stain based decatenation assay2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Design, Synthesis, Dynamic Docking, Biochemical Characterization, and
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1471734Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
AID1547967Antiproliferative activity against human HeLa cells by MTT assay2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Design, Synthesis, Dynamic Docking, Biochemical Characterization, and
AID1471732Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1471727Poison activity at human Topo2alpha expressed in baculovirus-infected insect cells using pBR322 as substrate assessed as topo2/DNA cleavage complex generation after 6 minutes by ethidium bromide staining based agarose gel electrophoresis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
AID1434590Inhibition of human topoisomerase-2 alpha expressed in baculovirus infected insect cells assessed as reduction in enzyme-meditaed supercoiled pRYG DNA substrate relaxation at 100 uM in presence of buffer containing 2-mercaptoethanol after 30 mins by agaro2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis and biological evaluation of naphthoquinone-coumarin conjugates as topoisomerase II inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID779718Cytotoxicity against human HeLa cells2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Further SAR studies on bicyclic basic merbarone analogues as potent antiproliferative agents.
AID591712Inhibition of human topoisomerase 2 alpha-mediated relaxation of supercoiled pHOT DNA after 30 mins by agarose gel electrophoresis2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Role of metalation in the topoisomerase IIα inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1471730Binding affinity to calf thymus DNA at 50 uM by UV-spectrophotometric analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
AID1547965Inhibition of human topo2alpha by plasmid relaxation assay2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Design, Synthesis, Dynamic Docking, Biochemical Characterization, and
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1547966Antiproliferative activity against human DU145 cells by MTT assay2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Design, Synthesis, Dynamic Docking, Biochemical Characterization, and
AID1547968Antiproliferative activity against human A549 cells by MTT assay2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Design, Synthesis, Dynamic Docking, Biochemical Characterization, and
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID779719Cytotoxicity against human MCF7 cells2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Further SAR studies on bicyclic basic merbarone analogues as potent antiproliferative agents.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1649927Inhibition of human xanthine oxidase2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacological urate-lowering approaches in chronic kidney disease.
AID1649928Inhibition of human URAT12019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacological urate-lowering approaches in chronic kidney disease.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1471735Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
AID1471728Inhibition of human topoisomerase 2alpha expressed in baculovirus-infected insect cells assessed as reduction in pBR322 supercoiled DNA relaxation after 60 mins by ethidium bromide staining based agarose gel electrophoresis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
AID779720Cytotoxicity against human MT4 cells2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Further SAR studies on bicyclic basic merbarone analogues as potent antiproliferative agents.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (11.59)18.7374
1990's31 (44.93)18.2507
2000's14 (20.29)29.6817
2010's12 (17.39)24.3611
2020's4 (5.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.12 (24.57)
Research Supply Index4.45 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (14.86%)5.53%
Reviews3 (4.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other60 (81.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]